Today announced that new data from its obesity program will be presented at Weight problems 2009 dapoxetin 30 mg.

Amylin Pharmaceuticals to present fresh data from its obesity program at Obesity 2009 Amylin Pharmaceuticals, Inc dapoxetin 30 mg more info . today announced that new data from its obesity program will be presented at Weight problems 2009, the 27th Annual Scientific Interacting with of The Obesity Culture, to be held in Washington, D.C. 24-28 October. Stage 2 data from the pramlintide/metreleptin combination treatment clinical program shall be the subject of a late-breaking oral presentation. Obesity 2009 is one of the largest scientific conferences in neuro-scientific obesity. Amylin may also present new scientific results from preclinical studies linked to its clinical-stage obesity programs for pramlintide/metreleptin and davalintide, an optimized amylin analog.

www.priligynorge.com

Ampio announces results from Optina trial about DME Ampio Pharmaceuticals, Inc. The primary endpoint was differ from baseline to week twelve of treatment in retinal thickness as measured by Optical Coherence Tomography . Secondary endpoints were 1) differ from baseline to week twelve in retinal volume and 2) change from baseline to week twelve in Early Treatment Diabetic Retinopathy Research Best Corrected Visible Acuity .